)
Overview
<ul>
<li>Rhythm Q3 2025 product revenue rises 54% yr/yr, driven by IMCIVREE sales</li>
<li>Net income for Q3 2025 misses analyst expectations, larger loss reported</li>
<li>FDA accepts sNDA for setmelanotide in acquired hypothalamic obesity, decision by Dec 20</li>
</ul>
Outlook
<ul>
<li>Company expects FDA decision on sNDA by December 20, 2025</li>
<li>Rhythm anticipates Q4 2025 results from Phase 2 trial in Prader-Willi syndrome</li>
<li>Company updates 2025 Non-GAAP Operating Expenses guidance to $295 mln-$315 mln</li>
</ul>
Result Drivers
<ul>
<li>U.S. SALES GROWTH - Revenue from U.S. sales increased 19% sequentially, driven by growth in IMCIVREE sales for BBS</li>
<li>INTERNATIONAL SALES DECLINE - Revenue outside the U.S. decreased 21% sequentially due to ordering variability and a one-time pricing adjustment in France</li>
</ul>
Key Details
Metric Beat/Mis Actual Consensu
s s
Estimate
<h3>Q3 $51.29</h3>
Product mln
Revenue
Q3 Net Miss -$52.90 -$45.50
Income mln mln (11
Analysts
)
Q3 Basic -$0.82
<h3>EPS</h3>
<h3>Q3 -$52.65</h3>
Operatin mln
g Income
Analyst Coverage
<ul>
<li>The current average analyst rating on the shares is “buy” and the breakdown of recommendations is 14 “strong buy” or “buy”, no “hold” and no “sell” or “strong sell”</li>
<li>The average consensus recommendation for the pharmaceuticals peer group is “buy”</li>
<li>Wall Street’s median 12-month price target for Rhythm Pharmaceuticals Inc is $121.50, about 6.4% above its November 3 closing price of $113.74</li>
</ul>
Press Release: For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact . (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

RYTM

Rhythm Pharma Q3 product revenue up 54% yr/yr on IMCIVREE sales